small cell lung carcinoma การใช้

• It is especially associated with non-small cell lung carcinoma.
• Small cell lung carcinoma, which practically only affects smokers have high risk from radon.
• Mutations in this gene have been seen frequently mutated in cases of non-small cell lung carcinoma.
• Surgery is very rarely used in cases of stage 3b or stage 4 non-small cell lung carcinoma.
• Some forms of cancer can cause SIADH, particularly small cell lung carcinoma but also a number of other tumors.
• The transforming " EML4-ALK " fusion gene was first reported in non-small cell lung carcinoma ( NSCLC ) in 2007.
• Accordingly, the proteasome subunit alpha type-1 was examined as a strategy in radio sensitizing for the treatment of non-small cell lung carcinomas.
• Early studies suggested that patients with small cell lung carcinoma ( SCLC ) fared better when treated with chemotherapy and / or radiation than when treated surgically.
• Most small cell lung carcinomas ( SCLC's ) metastasize to distant organs early on in their course, rendering surgery ineffective in curing the cancer.
• In 2006, Gaudernack and colleagues published results from a phase I / II clinical trial in patients with non-small cell lung carcinomas ( NSCLC ).
• For patients with advanced non-small cell lung carcinoma ( NSCLC ), maintenance therapy is sometimes used when the initial chemotherapy does not lead to improvement.
• The overexpression of OLIG2 was later shown present in malignancies beyond glioma and leukemia, such as breast cancer, melanoma and non-small cell lung carcinoma cell lines.
• The angiogenesis inhibitor bevacizumab ( Avastin ), ( in combination with paclitaxel and carboplatin ), improves the survival of patients with advanced non-small cell lung carcinoma.
• In Non-small cell lung carcinoma ( NSCLC ), surgically removed tumors that receive no further therapy have a better survival if ERCC1-positive than if ERCC1-negative.
• In non-small cell lung carcinoma and small cell lung carcinoma, higher expression of ABCC1 was indicative of a reduced response to chemotherapeutic drugs and a lower rate of survival.
• In non-small cell lung carcinoma and small cell lung carcinoma, higher expression of ABCC1 was indicative of a reduced response to chemotherapeutic drugs and a lower rate of survival.
• A combination of PSMA1 knockdown in parallel with radiation therapy to treat non-small cell lung carcinoma resulted in an increased sensitivity of the tumor to radiation and improved tumor control.
• While undifferentiated large-cell lung carcinoma is the most common parent lung tumor from which a rhabdoid phenotype evolves, combined large cell neuroencrine carcinoma, and combined small cell lung carcinoma.
• It is undergoing clinical trials for the treatment of non-small cell lung carcinoma ( NSCLC ), small cell lung cancer ( SCLC ), bladder cancer and metastatic hormone-refractory prostate cancer.
• In humans, the leading cause of cancer deaths worldwide is lung cancer, including non small cell lung carcinoma ( NSLC ) which accounts for 85 % of all lung cancer cases in the United States.